The rapid EPS growth and significant insider investment in Swire Pacific make it a company worth considering for investment. The hope is that the strong growth indicates a fundamental improvement in the business economics.
Investors are anticipating strong future growth for Swire Pacific, thus justifying its high P/E ratio. The likelihood of reduced earnings isn't seen adequate to justify a drop in P/E ratio, making a substantial share price drop unlikely soon.
Swire Pacific Limited is still undervalued, indicating potential investment opportunity. Given its optimistic outlook, it appears that the growth has not yet been fully factored into the share price. However, one warning sign was found in the analysis.
At close,$恒生指數(800000.HK)$gained 135 pts or 0.83% to 16,463;$國企指數(800100.HK)$rose 54 pts or 1% to 5,663; and$恒生科技指數(800700.HK)$added 64 pts or 1.8% to 3,747. The total market turnover for the day was $98.864 billion. $太古股份公司A(00019.HK)$rocketed 17.2% after Swire proposed to buy back up to $6 billion of its shares over the next two years. Local property developer$恒基地產(00012.HK)$ra...
$恒生指數(800000.HK)$opened 15 points or 0.1% lower at 16,311.$國企指數(800100.HK)$opened 2 points or 0.04% higher at 5,611.$恒生科技指數(800700.HK)$opened 8 points or 0.2% higher at 3,691. $藥明生物(02269.HK)$plans to spend up to US$600 million to buy back shares, and its shares opened rebounding 2.1% higher.$金沙中國有限公司(01928.HK)$shares open 3% higher after controlling shareholder plans to spend up to $1.95 billion...
SWIRE is planning to sell 100% equity interest of Swire Pacific Holdings Inc. (doing business as Swire Coca-Cola$可口可樂(KO.US)$, USA), and is anticipated to realize a gain of $22.8 billion.$太古股份公司A(00019.HK)$and$太古股份公司B(00087.HK)$grew 8% and 9.3% to $62.45 and $10.06, respectively.
太古股份公司A(ADR)股票討論區
HSI Climbs 135 Pts; SWIRE PACIFIC A Rallies 17%; Developers Up
$太古股份公司A(00019.HK)$ rocketed 17.2% after Swire proposed to buy back up to $6 billion of its shares over the next two years. Local property developer $恒基地產(00012.HK)$ ra...
HSI Opens 15 pts Down; WUXI BIO Rebounds
$藥明生物(02269.HK)$ plans to spend up to US$600 million to buy back shares, and its shares opened rebounding 2.1% higher. $金沙中國有限公司(01928.HK)$ shares open 3% higher after controlling shareholder plans to spend up to $1.95 billion...
Swire Pacific A Bounces 8%
暫無評論